Logo

Endo to Acquire BioSpecifics for ~ $540M

Share this

M&A

Endo to Acquire BioSpecifics for ~ $540M

Shots:

  • Endo to acquire all the outstanding shares of BioSpecifics for $88.50/ share in cash- making a total deal value of $540M. The transaction is expected to close in late 2020 while Endo expects to fund the transaction with cash on hand
  • BioSpecifics receives a royalty stream related to Endo's collagenase-based therapies- which include Xiaflex for Dupuytren's contracture and Peyronie's disease- and Qwo for cellulite- which is expected to be launched by Endo in spring 2021
  • Endo's acquisition subsidiary will be merged into BioSpecifics- and the remaining shares of BioSpecifics will be canceled and converted into the right to receive the same consideration payable pursuant to the tender offer

­ Ref: PRNewswire | Image: Seeking Alpha

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions